- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02301702
Maternal Tdap Immunization in Guatemala
Evaluation of Tdap in Pregnancy to Prevent Infant Pertussis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a randomized, blinded, controlled, vaccine trial of maternal Tdap vaccination during the third trimester of pregnancy (Tdap vaccination at 27-36 weeks gestation). Pregnant women will be recruited from the prenatal care clinics at the Hospital Nacional de Occidente and the Health Centers in Quetzaltenango, La Esperanza, San Juan Ostuncalco and Concepción Chiquirichapa.
All healthy pregnant women between the ages of 18 and 40 years (inclusive) at 27 weeks gestation or later who are in the study areas will be eligible to participate in this study unless they meet one or more of the exclusion criteria. Pregnant women at <27 weeks gestation will be pre-screened and provided information about the study to encourage them to enroll later in their pregnancy. Women who are eligible will be enrolled after obtaining informed consent, and then they will be randomized to receive Tdap vaccine or Td vaccine. Enrolled women and their infants will be followed up until 7 months postpartum.
To address the primary objective, serum specimens will be collected from mothers prior to receiving the study product (Tdap or Td), within 72 hours after delivery and at 7 months post-partum. Moreover, infants specimens will be collected at delivery (cord blood or infant blood within 72 hours of birth), at 2 months of age (prior to the first dose of the routine childhood DTwP series), and at 7 months of age (approximately 4 weeks after the third dose of the routine DTwP series).
Infants will be given all three doses of the pentavalent vaccine which includes DTwP vaccine at 2, 4 and 6 months (routine childhood immunizations) as recommended by the immunization schedule of Guatemala's National Immunization Program.
Adverse events and serious adverse events will also be monitored.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Guatemala, Guatemala, 01015
- Universidad del Valle de Guatemala
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant woman in late second or third trimester of pregnancy (i.e., after 27 weeks gestation),
- Between the ages of 18 and 40 years (inclusive),
- Intends to remain in the study area for at least seven months after delivery,
- Has access to a mobile phone (defined as a phone in the possession of the participant or another family member with whom she lives),
- Able to provide informed consent. If participant is illiterate, procedures to ensure full understanding of the research and consent process will be implemented according to international and federal guidelines.
Exclusion Criteria:
- History of fever or oral temperature ≥ 38.0 degree Celsius within 48 hours prior to vaccination (women can be re-evaluated at a subsequent visit),
- Received Tdap vaccine in the previous year,
- History of serious systemic disease, including but not limited to: Guillain-Barré syndrome; known HIV, hepatitis B, or hepatitis C infection; heart/lung disease; uncontrolled diabetes mellitus (including gestational diabetes); chronic liver/kidney disease; clinically significant neurological disorders. This information will be based on self-reporting and (where possible) will be confirmed by health facility medical records.
- High risk pregnancy, as identified by the Normas de Atención en Salud Integral, a guideline document published by the Ministry of Health, and also any previous complicated pregnancy or preterm delivery, spontaneous or medical abortion, or previous congenital anomaly,
- Received immunoglobulin or other blood product within the preceding 3 month (with the exception of Rhogam),
- History of allergy to any component of the vaccines (i.e. eggs, egg proteins, gelatin, formaldehyde, glutaraldehyde, polyethylene glycol p-isooctylphenyl ether, sucrose, aluminum hydroxide, polysorbate 80) or to latex,
- History of severe reaction (including hypersensitivity) after receiving any vaccine,
- History or evidence of immunosuppression (due to illness or treatment) or is on immunosuppressive therapy (includes long term use of steroids; use of high-dose inhaled steroids within past six months; with the exception of treatment with betamethasone or dexamethasone injections for the prevention of lung immaturity in the last trimester of pregnancy,
- In the opinion of the study team - it would be unsafe or unsuitable for the pregnant mother or her fetus to receive the vaccine or participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tdap Vaccine
Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
|
Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Other Names:
|
Active Comparator: Td Vaccine
Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
|
The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Infant pertussis antibody geometric mean concentrations (GMC) and 95% confidence intervals at birth (cord blood OR infant blood within 72 hours of birth), at 2 months of age, and 7 months of age
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Ratio of infant to mother pertussis antibody levels at the time of delivery
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Proportion of infants with at least a four-fold rise in serum antibody titer between 2 months and seven months of age (i.e., at four weeks after the 3rd dose of childhood DTwP)
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Maternal pertussis antibody GMC and 95% confidence intervals at baseline (pre-vaccination), within 72 hours after delivery, and seven months post-partum
Time Frame: Pre-vaccination to 7 months post-partum
|
Pre-vaccination to 7 months post-partum
|
Proportion of mothers sero-converting (serum pertussis antibody titer increase of ≥ 4-fold compared to pre-vaccination antibody levels) and 95% confidence intervals at the time of delivery (within 72 hours after delivery) and seven months post-partum
Time Frame: Pre-vaccination to 7 months post-partum
|
Pre-vaccination to 7 months post-partum
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of illnesses meeting the syndromic case definition (defined below); prematurity; pneumonia (per WHO Integrated Management of Childhood Illness [IMCI] classification)
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Birth weight and infant growth/anthropometric measurements (e.g., height and weight for age).
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Incidence of unsolicited non-serious (grades 1 & 2) adverse events 7 days post-delivery (for neonates)
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Infant growth/anthropometric measurements (e.g., height and weight z-scores at birth and 7 months of age)
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Incidence of serious (grades 3 & 4) adverse events through 7 months of age
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Laboratory (real-time PCR) confirmed pertussis infection in infants younger than 6 months of age
Time Frame: Birth to 7 months of age
|
Birth to 7 months of age
|
Incidence of unsolicited non-serious (grades 1&2) AEs 28 days post vaccination
Time Frame: Pre-vaccination to 7 months post-partum
|
Pre-vaccination to 7 months post-partum
|
Incidence of serious (grades 3 & 4) adverse events through 7 months post-partum
Time Frame: Pre-vaccination to 7 months post-partum
|
Pre-vaccination to 7 months post-partum
|
Infant pertussis antibody geometric mean concentrations (GMC) and 95% confidence intervals at 19 months after delivery
Time Frame: Pre-vaccination to 19 mo post-partum
|
Pre-vaccination to 19 mo post-partum
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Saad B. Omer, MBBS,MPH,PhD, Emory University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00072201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsRecruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
Association Clinique Thérapeutique Infantile du...Sanofi; GlaxoSmithKline; Merck Sharp & Dohme LLCRecruitingChildren, Only | Ambulatory | Pertussis/Whooping CoughFrance
-
University Hospital, GhentGlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; Novartis Vaccines; University... and other collaboratorsCompletedPrevention of Infections With Bordetella PertussisBelgium
Clinical Trials on Tdap
-
Sanofi Pasteur, a Sanofi CompanyCompletedTetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)Canada
-
PfizerCompleted
-
NovartisCompleted
-
Centre Hospitalier Universitaire Saint PierreCompletedPertussis | Pregnancy | HIV-1-infection | Immunization; InfectionBelgium
-
Vanderbilt UniversityDuke University; Centers for Disease Control and PreventionCompleted
-
Mahidol UniversityCompletedPertussis | Pregnancy RelatedThailand
-
PfizerCompleted
-
Farzanah LaherSanofiActive, not recruitingdTap VaccineSouth Africa
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
University of Prince Edward IslandThe Queen Elizabeth HospitalCompleted